Michael McMillan

Michael McMillan is a declared insider of Antibe Therapeutics Inc., with filings sourced from SEDI. Over a trading history stretching from 21 March 2018 to 3 October 2019, the count stands at 4 filings.

Both buying and selling appear: 1 purchase worth €20k, against 2 sales worth €166k. The net balance comes to €145k on the selling side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 1 option exercise.

The latest filing, published on 18 October 2019, reports an option exercise in Antibe Therapeutics Inc. The last insider purchase was made public on 24 September 2018, 2,954 days ago. Typically, a trade is published a median of 5 days after it takes place. This delay matters because a trade only becomes useful information once it is public. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEDI. They describe what insiders did and are not a recommendation.